



# FDA Approval Decisions Report November-January 2006

## Overview

For investors in pharmaceutical and biotech companies, rigorous monitoring of drug pipelines is essential. No milestone is more influential than the FDA approval decision date, frequently called the PDUFA date (from Prescription Drug User Fee Act).

This Revere Report features **companies with expected FDA approval decision dates in the next three months**. To provide further insights into **each drug candidate's likelihood of approval and competitive landscape**, the FDA Approval Decisions Report includes **key data based on Revere's patented classification system and proprietary pipeline database** – specifically, whether each drug candidate:

- utilizes a mechanism of action already approved by the FDA in other drugs
- faces two or fewer alternative drugs with the same mechanism of action for the same indication
- would be the first or second FDA approved drug for the company

## Contents

- Recent Approval Results/Updates
- Expected PDUFA Dates in the Next Three Months
- Price and Financial Info

---

Copyright 2006 by Revere Data, LLC. All rights reserved.

### Notes:

1. Some expected PDUFA (Prescription Drug User Fee Act) dates are Revere estimates based on NDA (New Drug Approval) submission dates. Companies are not obligated to disclose NDA submission dates or PDUFA dates, and the FDA may change its approval decision date without prior notice.
2. Drugs developed by private firms or by companies not traded publicly in the U.S. are excluded from this analysis.

### Disclaimer:

Revere Data is an independent provider of investment research and information and does not offer broker / dealer, money management, hedge fund management, investment advisory, or investment banking services.

The information contained in this report is based on a limited analysis of qualitative, statistical, and financial data and should not be interpreted as recommendations based on a complete investment evaluation. The information is based on sources that Revere Data believes to be reliable, but no representation, express or implied, is made with respect to the accuracy, completeness, reliability, or timeliness. The information is subject to change without notice, and Revere Data does not accept responsibility to update it.

Revere Data does not accept responsibility or liability for any direct, indirect, special, consequential, or other losses or damages of any kind whatsoever arising out of access to, or use of, this report or any information contained in it.

**For more information on Revere's independent research data and investment analytics, please contact us as follows:**

**Revere Data, LLC** | 2 Rector Street, Suite 900 | New York, NY 10006  
866.REVERE9 (866.738.3739) | sales@reveredata.com | www.reveredata.com

## Recent Approval Results/Updates

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Previous Expected PDUFA Date	Approval results/update
<b>New River Pharmaceuticals, Inc. (NRPH) / NRP104 (Lisdexamfetamine Dimesylate)</b>				
	Attention Deficit Hyperactivity Disorder (ADHD) In Pediatric Patients 6-12 Years Of Age	Sympathomimetic Agents	<u>10/06/2006</u>	<b>Approvable Letter Received</b> 10/06/2006
<b>Merck &amp; Co., Inc. (MRK) / Zolinza (Vorinostat)</b>				
	Cutaneous T-Cell Lymphoma (Non-Hodgkin's Lymphoma (NHL))	Histone Deacetylase (HDAC) Inhibitors	<u>10/06/2006</u>	<b>Approved</b> 10/06/2006
<b>Shire plc (ADR) (SHPGY) / NRP104 (Lisdexamfetamine Dimesylate)</b>				
	Attention Deficit Hyperactivity Disorder (ADHD) In Pediatric Patients 6-12 Years Of Age	Sympathomimetic Agents	<u>10/06/2006</u>	<b>Approvable Letter Received</b> 10/06/2006
<b>Roche Holding Ltd. (ADR) (RHHBY) / Avastin (Bevacizumab)</b>				
	First-Line Treatment Of Non-Small Cell Lung Cancer (NSCLC) In Combination With Chemotherapies	Monoclonal Antibodies	<u>10/11/2006</u>	<b>Approved</b> 10/11/2006
<b>Genentech, Inc. (DNA) / Avastin (Bevacizumab)</b>				
	First-Line Treatment Of Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) In Combination With Chemotherapies	Monoclonal Antibodies	<u>10/11/2006</u>	<b>Approved</b> 10/11/2006
<b>Indevus Pharmaceuticals (IDEV) / SANCTURA XR (Trospium Chloride)</b>				
	Overactive Bladder With Symptoms Of Urinary Incontinence, Urgency, And Frequency	Muscarinic Receptor Antagonists	10/12/2006	Result Pending
<b>Sepracor Inc. (SEPR) / Brovana (Arformoterol Tartrate)</b>				
	Chronic Obstructive Pulmonary Disease (COPD)	Beta Adrenergic Receptor Agonists	10/12/2006	<b>Approved</b> 10/06/2006
<b>MGI Pharma, Inc. (MOGN) / Saforis (L-Glutamine)</b>				
	Oral Mucositis Associated With Mucotoxic Cancer Therapy	Immunomodulatory Agents	<u>10/12/2006</u>	<b>Approvable Letter Received</b> 10/12/2006
<b>Schering-Plough Corporation (SGP) / Geninax (Garenoxacin Mesylate)</b>				
	Acute Bacterial Exacerbation Of Chronic Bronchitis, Acute Bacterial Sinusitis, Community-Acquired Pneumonia, Complicated And Uncomplicated Skin And Skin Structure Infections, And Complicated Intra-Abdominal Infections	Macrolides	10/13/2006	Result Pending
<b>Eisai Co., Ltd (ADR) (ESALY) / Aricept (Donepezil Hydrochloride)</b>				
	Severe Alzheimer's Disease	Acetylcholinesterase Inhibitors	<u>10/16/2006</u>	<b>Approved</b> 10/16/2006
<b>Pfizer Inc. (PFE) / Aricept (Donepezil Hydrochloride)</b>				
	Severe Alzheimer's Disease	Acetylcholinesterase Inhibitors	<u>10/16/2006</u>	<b>Approved</b> 10/16/2006
<b>Merck &amp; Co., Inc. (MRK) / Januvia (Sitagliptin Phosphate)</b>				
	Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes	Dipeptidyl Peptidase (DPP) Inhibitors	10/16/2006	<b>Approved</b> 10/16/2006
<b>Roche Holding Ltd. (ADR) (RHHBY) / Avastin (Bevacizumab)</b>				

Company (Symbol) / Drug Candidate			
Second-Line Treatment Of Metastatic Colorectal Cancer (Colon Cancer) In Combination With 5-Fluorouracil (5-FU)-Based Chemotherapy	Monoclonal Antibodies	10/19/2006	Approved 06/20/2006
Genentech, Inc. (DNA) / Avastin (Bevacizumab)			
Second-Line Treatment Of Metastatic Colorectal Cancer (Colon Cancer) In Combination With 5-Fluorouracil (5-FU)-Based Chemotherapy	Monoclonal Antibodies	10/19/2006	Approved 06/20/2006
Adeza Biomedical Corporation (ADZA) / Gestiva			
Preterm Birth Prevention In Women With A History Of Preterm Delivery	Progestins	10/20/2006	Approvable Letter Received 10/23/2006
Forest Laboratories, Inc. (FRX) / Orapem (Faropenem Medoxomil)			
Acute Bacterial Sinusitis, Community-Acquired Pneumonia, Acute Exacerbation Of Chronic Bronchitis, Uncomplicated Skin And Skin Structure Infections In Adults	Carbapenems	10/20/2006	Non-Approvable Letter Received 10/23/2006
Replidyne, Inc. (RDYN) / Orapem (Faropenem Medoxomil)			
Acute Bacterial Sinusitis, Community-Acquired Pneumonia, Acute Exacerbation Of Chronic Bronchitis, Uncomplicated Skin And Skin Structure Infections In Adults	Carbapenems	10/20/2006	Non-Approvable Letter Received 10/23/2006
Shire plc (ADR) (SHPGY) / Mesavance/SPD 476 (Mesalamine)			
Mild-To-Moderate Ulcerative Colitis	Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors	10/23/2006	Rescheduled to 01/19/2007
Wyeth (WYE) / Desvenlafaxine Succinate/DVS-233			
Major Depressive Disorder	Selective Norepinephrine Reuptake Inhibitors (SNRI)	10/23/2006	Rescheduled to 01/22/2007
Schering-Plough Corporation (SGP) / Noxafil (Posaconazole)			
Oropharyngeal Candidiasis (Fungal Infection Of The Mouth And Throat Caused By The Yeast Candida)	Imidazoles	10/23/2006	Approved 10/23/2006
GlaxoSmithKline plc (ADR) (GSK) / Coreg CR (Carvedilol Controlled Release)			
Once Daily Dose For Hypertension	Beta Adrenergic Receptor Blocking Agents (Beta Blockers)	10/23/2006	Approved 10/20/2006
Genta Incorporated (GNTA) / Genasense (Oblimersen Sodium)			
Chronic Lymphocytic Leukemia (CLL) In Combination With Fludarabine and Cyclophosphamide	Antisense Agents	10/27/2006	Rescheduled to 01/29/2007
AstraZeneca plc (ADR) (AZN) / Seroquel (Quetiapine Fumarate)			
Depressive Episodes Associated With Bipolar Disorder	Monoaminergic Antagonists	10/30/2006	Approved 10/20/2006
AVANIR Pharmaceuticals (AVNR) / Zenvia/Formely Neurodex (Dextromethorphan/Quinidine Sulfate)			
Pseudobulbar Affect (Emotional Lability)	Antitussives/Sodium Channel Blocking Agents	10/30/2006	Approvable Letter Received 10/30/2006
Idenix Pharmaceuticals, Inc. (IDIX) / Tyzeka (Telbivudine)			
Chronic Hepatitis B Virus (HBV) Infection	Reverse Transcriptase Inhibitors (Nucleoside Analogs)	10/31/2006	Approved 10/25/2006
Bradley Pharmaceuticals, Inc. (BDY) / Polyphenon E Ointment			
Genital Warts, Perianal Warts	Catechins	10/31/2006	Approved 10/31/2006

Company (Symbol) / Drug Candidate			
<b>Novartis AG (ADR) (NVS) / Tyzeka (Telbivudine)</b>			
Chronic Hepatitis B Virus (HBV) Infection	Reverse Transcriptase Inhibitors (Nucleoside Analogs)	<u>10/31/2006</u>	<b>Approved</b> 10/25/2006
<b>Altana AG (ADR) (AAA) / Omnaris (Nasal Spray Ciclesonide)</b>			
Nasal Symptoms Associated With Seasonal And Perennial Allergic Rhinitis	Steroidal Anti-Inflammatory Drugs (SAID)	11/07/2006	<b>Approved</b> 10/23/2006
<b>Novartis AG (ADR) (NVS) / Gleevec (Imatinib Mesylate)</b>			
Systemic Mastocytosis (SM, A Rare Form Of Leukemia)	Tyrosine Kinase Inhibitors	02/12/2007	<b>Approved</b> 10/19/2006
<b>Novartis AG (ADR) (NVS) / Gleevec (Imatinib Mesylate)</b>			
Myeloproliferative Disorders (MPD, A Rare Blood Related Cancer)	Tyrosine Kinase Inhibitors	02/12/2007	<b>Approved</b> 10/19/2006
<b>Novartis AG (ADR) (NVS) / Gleevec (Imatinib Mesylate)</b>			
Hypereosinophilic Syndrome (HES, A Rare Form Of Leukemia)	Tyrosine Kinase Inhibitors	02/12/2007	<b>Approved</b> 10/19/2006
<b>Novartis AG (ADR) (NVS) / Gleevec (Imatinib Mesylate)</b>			
Dermatofibrosarcoma Protuberans (DPSP, A Rare Malignant Skin Cancer)	Tyrosine Kinase Inhibitors	02/12/2007	<b>Approved</b> 10/19/2006

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases.

## Expected PDUFA Dates in the Next Three Months

### November Drug Candidates

#### Companies

Adolor Corporation (ADLR)  
**Genentech, Inc. (DNA) [2]**  
 GlaxoSmithKline plc (ADR) (GSK)  
 Novadel Pharma Inc (NVD)  
 Novartis AG (ADR) (NVS)  
 Par Pharmaceutical Companies, Inc (PRX)  
**Roche Holding Ltd. (ADR) (RHHBY) [2]**

#### Sectors

- I Biopharmaceuticals
  - Cardiovascular System
  - Endocrinology/Metabolism
  - Oncology
  - Surgery

#### Notes:

- Some drug candidates are filed jointly by two companies.
- Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [ ].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 <sup>st</sup> /2 <sup>nd</sup> Drug?
<b>Novadel Pharma Inc (NVD) / NitroMist (Nitroglycerin Lingual Aerosol)</b>						
	Acute Relief Or Acute Prophylaxis Of Angina Pectoris	Vasodilatory Agents	<u>11/03/2006</u>	Yes	<b>No</b> Multiple Drugs	Yes
<b>Par Pharmaceutical Companies, Inc (PRX) / NitroMist (Nitroglycerin Lingual Aerosol)</b>						
	Acute Relief Or Acute Prophylaxis Of Angina Pectoris	Vasodilatory Agents	<u>11/03/2006</u>	Yes	<b>No</b> Multiple Drugs	No
<b>GlaxoSmithKline plc (ADR) (GSK) / Entereg (Alvimopan)</b>						
	Post-Operative Ileus (POI)	Opioid Receptor Antagonists	<u>11/09/2006</u>	No	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>Adolor Corporation (ADLR) / Entereg (Alvimopan)</b>						
	Post-Operative Ileus (POI)	Opioid Receptor Antagonists	<u>11/09/2006</u>	No	<b>Yes</b> Only Candidate with This PMOA for This Indication	Yes
<b>Genentech, Inc. (DNA) / Herceptin (Trastuzumab)</b>						
	Early Stage, HER2-Positive Breast Cancer	Monoclonal Antibodies	<u>11/17/2006</u>	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>Roche Holding Ltd. (ADR) (RHHBY) / Herceptin (Trastuzumab)</b>						
	Early Stage, HER2-Positive Breast Cancer	Monoclonal Antibodies	<u>11/17/2006</u>	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>Genentech, Inc. (DNA) / Avastin (Bevacizumab)</b>						
	First-Line Treatment Of Locally Recurrent Or Metastatic Breast Cancer In Combination With Chemotherapies	Monoclonal Antibodies	<u>11/22/2006</u>	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>Roche Holding Ltd. (ADR) (RHHBY) / Avastin (Bevacizumab)</b>						
	First-Line Treatment Of Locally Recurrent Or Metastatic Breast Cancer In Combination With Chemotherapies	Monoclonal Antibodies	<u>11/22/2006</u>	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>Novartis AG (ADR) (NVS) / Galvus (Vildagliptin)</b>						
	Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes	Dipeptidyl Peptidase (DPP) Inhibitors	<u>11/30/2006</u>	No	<b>Yes</b> Januvia (Sitagliptin Phosphate) / (MRK)	No

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? 1<sup>st</sup>/2<sup>nd</sup> Drug -- 1st or 2nd FDA Approved Drug of the Company?



## December Drug Candidates

### Companies

BioSante Pharmaceuticals, Inc. (BPA)  
 Cephalon, Inc. (CEPH)  
 Millennium Pharmaceuticals, Inc. (MLNM)  
**Novartis AG (ADR) (NVS) [2]**  
 Oscient Pharmaceuticals Corporation (OSCI)

### Sectors

- I Biopharmaceuticals
  - Cardiovascular System
  - Endocrinology/Metabolism
  - Infectious Diseases
  - Neurology
  - Oncology

#### Notes:

1. Some drug candidates are filed jointly by two companies.
2. Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [ ].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 <sup>st</sup> /2 <sup>nd</sup> Drug?
<b>Millennium Pharmaceuticals, Inc. (MLNM) / Velcade (Bortezomib)</b>						
	Relapsed Or Refractory Mantle Cell Lymphoma	Proteasome Inhibitors	<u>12/08/2006</u>	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>Oscient Pharmaceuticals Corporation (OSCI) / FACTIVE (Gemifloxacin Mesylate)</b>						
	5 Day Therapy For Acute Bacterial Sinusitis	Quinolones/Fluoroquinolones	<u>12/15/2006</u>	Yes	<b>Yes</b> Ketek (Telithromycin) / (SNY) Cipro Tablests/Cipro Oral Suspension/Cipro XR (Ciprofloxacin) / (BAY)	No
<b>BioSante Pharmaceuticals, Inc. (BPA) / Bio-E-Gel (Estradiol Gel)</b>						
	Moderate-To-Severe Hot Flashes In Menopausal Women	Estrogens	12/15/2006	Yes	<b>No</b> Multiple Drugs	Yes
<b>Novartis AG (ADR) (NVS) / Rasilez (Aliskiren)</b>						
	Hypertension	Renin Inhibitors	12/20/2006	No	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>Novartis AG (ADR) (NVS) / Exforge (Valsartan/Amlodipine)</b>						
	Hypertension	Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Calcium Channel Blockers	12/27/2006	Yes	<b>No</b> Multiple Drugs	No
<b>Cephalon, Inc. (CEPH) / Nuvigil (Armodafinil)</b>						
	Excessive Sleepiness Associated With Narcolepsy, Shift Work Sleep Disorder, And Obstructive Sleep Apnea/Hypopnea Syndrome	Alpha Adrenergic Receptor Agonists	12/29/2006	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? **1<sup>st</sup>/2<sup>nd</sup> Drug** -- 1st or 2nd FDA Approved Drug of the Company?

## January Drug Candidates

### Companies

Amylin Pharmaceuticals (AMLN)  
**Connetics Corporation (CNCT) [2]**  
 Eli Lilly & Co. (LLY)  
 Enzon Pharmaceuticals, Inc. (ENZN)  
 Genta Incorporated (GNTA)  
 GlaxoSmithKline plc (ADR) (GSK)  
 KOS Pharmaceuticals, Inc. (KOSP)  
 Nektar Therapeutics (NKTR)  
 Pfizer Inc. (PFE)  
 Schwarz Pharma, Inc. (SWTZY)  
 Shire plc (ADR) (SHPGY)  
 Wyeth (WYE)

### Sectors

**I** Biopharmaceuticals  

 Cardiovascular System  
 Dermatology  
 Endocrinology/Metabolism  
 Immunology  
 Neurology  
 Oncology  
 Urology

#### Notes:

- Some drug candidates are filed jointly by two companies.
- Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [ ].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 <sup>st</sup> /2 <sup>nd</sup> Drug?
<b>Amylin Pharmaceuticals (AMLN) / Byetta (Exenatide)</b>						
	Add-On Therapy To Thiazolidinediones (TZDs) In People With Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes Who Are Not Achieving Acceptable Blood Sugar Control	Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 Receptor Agonists)	01/02/2007	Yes	<b>Yes</b> Liraglutide (NN 2211) / (NVO)	No
<b>Eli Lilly &amp; Co. (LLY) / Byetta (Exenatide)</b>						
	Add-On Therapy To Thiazolidinediones (TZDs) In People With Type 2 Diabetes Who Are Not Achieving Acceptable Blood Sugar Control	Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 Receptor Agonists)	01/02/2007	Yes	<b>Yes</b> Liraglutide (NN 2211) / (NVO)	No
<b>Nektar Therapeutics (NKTR) / Cimzia (Certolizumab Pegol)</b>						
	Crohn's Disease	Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)	01/02/2007	Yes	<b>Yes</b> Humira (Adalimumab) / (ABT) Centocor Remicade (Infliximab) / (JNJ)	No
<b>Enzon Pharmaceuticals, Inc. (ENZN) / Cimzia (Certolizumab Pegol)</b>						
	Crohn's Disease	Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)	01/02/2007	Yes	<b>Yes</b> Humira (Adalimumab) / (ABT) Centocor Remicade (Infliximab) / (JNJ)	No
<b>Schwarz Pharma, Inc. (SWTZY) / Fesoterodine</b>						
	Overactive Bladder/Urinary Incontinence	Muscarinic Receptor Antagonists	January 2007	Yes	<b>No</b> Multiple Drugs	No
<b>Pfizer Inc. (PFE) / Fesoterodine</b>						
	Overactive Bladder/Urinary Incontinence	Muscarinic Receptor Antagonists	January 2007	Yes	<b>No</b> Multiple Drugs	No
<b>KOS Pharmaceuticals, Inc. (KOSP) / Niaspan CF (Niacin)</b>						
	Hypercholesterolemia	Free Fatty Acid Inhibitors	01/12/2007	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>Connetics Corporation (CNCT) / Primolux (Clobetasol Propionat)</b>						

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 <sup>st</sup> /2 <sup>nd</sup> Drug?
<b>Company (Symbol) / Drug Candidate</b>						
	Atopic Dermatitis (Eczema)	Steroidal Anti-Inflammatory Drugs (SAID)	<u>01/17/2007</u>	Yes	<b>Yes</b> Dermik Laboratories Psorcon E (Diflorasone Diacetate) / (SNY) Synalar (Fluocinolone Acetonide) / (MRX)	No
<b>Connetics Corporation (CNCT) / Primolux (Clobetasol Propionat)</b>						
	Psoriasis	Steroidal Anti-Inflammatory Drugs (SAID)	<u>01/17/2007</u>	Yes	<b>Yes</b> Dermik Laboratories Psorcon E (Diflorasone Diacetate) / (SNY) Synalar (Fluocinolone Acetonide) / (MRX)	No
<b>Shire plc (ADR) (SHPGY) / Mesavance/SPD 476 (Mesalamine)</b>						
	Mild-To-Moderate Ulcerative Colitis	Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors	<u>01/19/2007</u>	Yes	<b>No</b> Multiple Drugs	No
<b>Wyeth (WYE) / Desvenlafaxine Succinate/DVS-233</b>						
	Major Depressive Disorder	Selective Norepinephrine Reuptake Inhibitors (SNRI)	<u>01/22/2007</u>	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>Genta Incorporated (GNTA) / Genasense (Oblimersen Sodium)</b>						
	Chronic Lymphocytic Leukemia (CLL) In Combination With Fludarabine and Cyclophosphamide	Antisense Agents	<u>01/29/2007</u>	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>GlaxoSmithKline plc (ADR) (GSK) / Arixtra (Fondaparinux Sodium)</b>						
	Acute Coronary Syndrome (ACS)	Thrombin Inhibitors	<u>01/31/2007</u>	Yes	<b>Yes</b> Angiomax (Bivalirudin) / (MDCO)	No

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? 1<sup>st</sup>/2<sup>nd</sup> Drug -- 1st or 2nd FDA Approved Drug of the Company?

## Price and Financial Info

### November 2006

Data as of 11/01/2006

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
Adolor Corporation	ADLR	13.50	619.757	655,032	n/a	n/a	n/a	28.82%	20.40%
Genentech, Inc.	DNA	81.93	86,268.690	3,958,296	n/a	n/a	n/a	-10.02%	-18.44%
GlaxoSmithKline plc (ADR)	GSK	52.92	152,917.213	1,544,074	15.16	60.09	6,459.8	2.00%	-6.42%
Novadel Pharma Inc	NVD	1.30	64.007	85,048	6.37	1.46	10.7	-9.72%	-18.14%
Novartis AG (ADR)	NVS	60.57	142,260.748	1,117,382	3.69	23.89	8,530.0	12.21%	3.79%
Par Pharmaceutical Companies, Inc	PRX	18.87	661.381	413,022	1.90	44.65	148.8	-25.27%	-33.69%
Roche Holding Ltd. (ADR)	RHHBY	88.05	151,897.260	n/a	8.33	24.11	16,040.6	17.01%	8.59%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,

### December 2006

Data as of 11/01/2006

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
BioSante Pharmaceuticals, Inc.	BPA	1.75	40.204	189,561	15.60	0	4.5	-40.68%	-49.10%
Cephalon, Inc.	CEPH	69.64	4,230.341	1,579,608	n/a	198.73	485.5	54.17%	45.75%
Millennium Pharmaceuticals, Inc.	MLNM	11.50	3,626.229	5,332,276	6.49	8.28	635.6	26.37%	17.95%
Novartis AG (ADR)	NVS	60.57	142,260.748	1,117,382	3.69	23.89	8,530.0	12.21%	3.79%
Oscient Pharmaceuticals Corporation	OSCI	1.07	115.988	557,046	n/a	828.33	71.6	-40.88%	-49.30%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,

### January 2007

Data as of 11/01/2006

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
Amylin Pharmaceuticals	AMLN	43.48	5,391.824	1,990,588	7.99	29.65	832.5	30.69%	22.27%
Connetics Corporation	CNCT	17.01	585.445	1,032,459	n/a	281.58	242.5	32.37%	23.95%
Eli Lilly & Co.	LLY	55.95	63,245.824	3,958,920	n/a	n/a	n/a	12.44%	4.02%
Enzon Pharmaceuticals, Inc.	ENZN	8.37	366.529	535,197	n/a	0	332.5	22.19%	13.77%
Genta Incorporated	GNTA	0.78	119.493	4,810,108	3.92	0.9	35.8	-49.18%	-57.60%
GlaxoSmithKline plc (ADR)	GSK	52.92	152,917.213	1,544,074	15.16	60.09	6,459.8	2.00%	-6.42%
KOS Pharmaceuticals, Inc.	KOSP	49.95	2,369.672	423,368	4.53	4.08	482.8	-14.99%	-23.41%
Nektar Therapeutics	NKTR	13.92	1,252.260	1,927,372	7.10	165.19	475.9	-6.07%	-14.49%
Pfizer Inc.	PFE	26.57	193,733.853	33,842,868	n/a	n/a	n/a	23.29%	14.87%
Schwarz Pharma, Inc.	SWTZY	116.15	n/a	n/a	n/a	n/a	n/a	102.71%	94.29%
Shire plc (ADR)	SHPGY	55.49	9,314.924	1,724,825	10.84	0	955.2	54.91%	46.49%
Wyeth	WYE	50.35	67,753.878	6,359,128	n/a	n/a	n/a	14.90%	6.48%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,